A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Late Preterm and Term Infants (MELODY)

Project: Other project

StatusActive
Effective start/end date9/12/199/11/21

Funding

  • AstraZeneca LP: $6,379.23